Cited by 212Rabies epidemiology and controlVirology and Viral DiseasesAnimal Virus Infections Studies

The DOI matches its Crossref record; 56 of the 60 references it cites were found in a registry or an index; 6 of the 27 sources its claims cite were checked for support.

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

Open access

Abstract

Rabies is a zoonotic infectious disease of the central nervous system (CNS). In unvaccinated or untreated subjects, rabies virus infection causes severe neurological symptoms and is invariably fatal. Despite the long-standing existence of effective vaccines, vaccine availability remains insufficient, with high numbers of fatal infections mostly in developing countries. Nucleic acid based vaccines have proven convincingly as a new technology for the fast development of vaccines against newly emerging pathogens, diseases where no vaccine exists or for replacing already existing vaccines. We used an optimized non-replicating rabies virus glycoprotein (RABV-G) encoding messenger RNA (mRNA) to induce potent neutralizing antibodies (VN titers) in mice and domestic pigs. Functional antibody titers were followed in mice for up to one year and titers remained stable for the entire observation period in all dose groups. T cell analysis revealed the induction of both, specific CD4+ as well as CD8+ T cells by RABV-G mRNA, with the induced CD4+ T cells being higher than those induced by a licensed vaccine. Notably, RABV-G mRNA vaccinated mice were protected against lethal intracerebral challenge infection. Inhibition of viral replication by vaccination was verified by qRT-PCR. Furthermore, we demonstrate that CD4+ T cells are crucial for the generation of neutralizing antibodies. In domestic pigs we were able to induce VN titers that correlate with protection in adult and newborn pigs. This study demonstrates the feasibility of a non-replicating mRNA rabies vaccine in small and large animals and highlights the promises of mRNA vaccines for the prevention of infectious diseases.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

A non-replicating, protamine-complexed mRNA vaccine encoding rabies virus glycoprotein induced neutralizing antibodies and T cells in mice and pigs, and protected mice against lethal intracerebral rabies challenge. Protection required CD4+ T cells during immunization, and adult and newborn pigs developed neutralizing titers above the WHO correlate of 0.5 IU/ml.

Key findings

  • Two 80 μg RABV-G mRNA vaccinations induced VN titers ≥0.5 IU/ml in all immunized mice (range 5.9–70.2 IU/ml); after doses ≥10 μg, 100% of C57BL/6 and 90% (29/32) of BALB/c mice seroconverted. Titers remained stable for about one year, with mean titers between 17 and 65 IU/ml for 20 μg, 80 μg, and Rabipur groups.
  • RABV-G mRNA induced antigen-specific CD4+ and CD8+ T cells. IFN-γ/TNFα-double-positive CD4+ T cells were higher after mRNA than Rabipur at 6 days after boost (mean 0.48% vs 0.091%) and at day 91 (mean 0.084% vs 0.034%).
  • All RABV-G mRNA and HDC vaccinated mice survived lethal intracerebral challenge with 40-fold LD50 CVS-11, while none of the buffer-treated mice survived. qRT-PCR showed viral N-protein RNA was suppressed below detection in all but one mRNA-vaccinated mouse.
  • CD4+ T cell depletion during immunization reduced mean VN titers to about 3 IU/ml versus about 50 IU/ml in CD4-intact mRNA-vaccinated mice, and all CD4-depleted mRNA-vaccinated mice died within 11 days after challenge. Adult and newborn pigs seroconverted above 0.5 IU/ml; newborn piglets given 80 μg had mean titers of 11.0 IU/ml at day 28 and 2.5 IU/ml at day 70, while 240 μg gave 56.8 IU/ml and 8.3 IU/ml, comparable to full-dose Rabipur.

Methods

  • Mice (BALB/c and C57BL/6, 6–8 weeks old) and domestic pigs (adult and newborn) were immunized intradermally with optimized non-replicating RABV-G mRNA complexed with protamine; controls included buffer, irrelevant mRNA, and licensed vaccines Rabipur or HDC.
  • Antibody responses were measured by FAVN test; T cell responses by intracellular cytokine staining and ELISPOT; CD4+ T cells were depleted with anti-CD4 monoclonal antibody; mice were challenged intracerebrally with 40-fold LD50 CVS-11; viral N-protein RNA and TNFα mRNA in brains were quantified by qRT-PCR.
  • Statistical comparisons used Mann Whitney, Kruskal-Wallis, one-way ANOVA with Tukey’s or Dunnett’s multiple comparisons tests.

Limitations

  • The paper states that one mRNA-vaccinated mouse had detectable viral N-protein RNA at day 6 and was non-protected, and that reduced TNFα mRNA levels in vaccinated brains were not statistically significant.
  • The paper notes that the 0.5 IU/ml threshold may be a surrogate for protection against natural peripheral rabies infection rather than the laboratory intracerebral challenge used here.
  • Evident from the text: this is a preclinical animal study; pigs were assessed for immunogenicity only, not challenge protection; group sizes were small; and no human efficacy or safety data are reported, although a phase I clinical study is mentioned as initiated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pntd.0004746

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Antigen-specific immune response in mice. (A) Virus-neutralizing (VN) antibody titers in the serum of female BALB/c mice were measured using Fluorescent Antibody Virus Neutralization (FAVN) test. Animals were vaccinated twice with 80 μg RABV-G mRNA or buffer at day 0 and 21. 35 days after the first vaccination, serum was collected. The dotted line at 0.5 IU/ml is considered as a correlate of protection. (B) Splenocytes from the same mice were isolated for the analysis of antigen specific T cells via ELISPOT analysis at day 35 after the first immunization. (C, D) VN titers dose-response profile in female (C) C57BL/6 and (D) BALB/c mice after RABV-G mRNA vaccination compared to licensed vaccines. Animals were vaccinated with RABV-G mRNA, licensed vaccines (HDC or Rabipur (LIC)) or buffer on study days 0 and 21. RABV-G mRNA was applied intradermally (i.d.) at doses of 80 μg, 40 μg, 20 μg, 10 μg, 5 μg, 2.5 μg or 1.25 μg. For positive control, 100 μl (0.1 human dose) of Rabipur and HDC were administered intramuscularly (i.m.). Presence of rabies-specific VN titers in sera of vaccinated and control mice were analyzed 2 weeks after immunization using the FAVN test. In both graphs the mean and standard deviation (SD) is plotted and significance compared to buffer treated mice was analysed using one-way ANOVA Dunnett’s multiple comparisons test (* p<0.01). (E) Kinetic of virus-neutralizing antibodies in BALB/c mice from (D). Immunization points are indicated by arrows. Mean an SD is presented (n = 8/group).
Fig 1 Antigen-specific immune response in mice. (A) Virus-neutralizing (VN) antibody titers in the serum of female BALB/c mice were measured using Fluorescent Antibody Virus Neutralization (FAVN) test. Animals were vaccinated twice with 80 μg RABV-G mRNA or buffer at day 0 and 21. 35 days after the first vaccination, serum was collected. The dotted line at 0.5 IU/ml is considered as a correlate of protection. (B) Splenocytes from the same mice were isolated for the analysis of antigen specific T cells via ELISPOT analysis at day 35 after the first immunization. (C, D) VN titers dose-response profile in female (C) C57BL/6 and (D) BALB/c mice after RABV-G mRNA vaccination compared to licensed vaccines. Animals were vaccinated with RABV-G mRNA, licensed vaccines (HDC or Rabipur (LIC)) or buffer on study days 0 and 21. RABV-G mRNA was applied intradermally (i.d.) at doses of 80 μg, 40 μg, 20 μg, 10 μg, 5 μg, 2.5 μg or 1.25 μg. For positive control, 100 μl (0.1 human dose) of Rabipur and HDC were administered intramuscularly (i.m.). Presence of rabies-specific VN titers in sera of vaccinated and control mice were analyzed 2 weeks after immunization using the FAVN test. In both graphs the mean and standard deviation (SD) is plotted and significance compared to buffer treated mice was analysed using one-way ANOVA Dunnett’s multiple comparisons test (* p<0.01). (E) Kinetic of virus-neutralizing antibodies in BALB/c mice from (D). Immunization points are indicated by arrows. Mean an SD is presented (n = 8/group).CC BY · PubMed Central
Fig 2 Induction of rabies virus specific T cells upon immunization of female BALB/c mice with RABV-G mRNA. Mice were vaccinated twice (days 0 and 21) with 80 μg RABV-G mRNA, 0.1 human dose Rabipur (LIC) or buffer. Activated, antigen specific (A) CD8+ T cells and (B) CD4+ T cells were analyzed by intracellular staining of IFN-γ alone (left panel), TNFα alone (middle panel) or IFN-γ and TNFα (right panel) followed by flow cytometry analysis. Isolation of splenocytes was done 6 days after the second immunization. (C+D) Analysis of long-lasting T cell immunoreactivity. Mice were treated with 80 μg RABV-G mRNA, 0.1 human dose Rabipur (LIC) or injection buffer alone at days 0 and 21. Ten weeks after boost, animals were sacrificed and IFN-γ and TNFα double positive antigen-specific (C) CD8+ and (D) CD4+ T cells were analysed by flow cytometry (n = 8/group). Mean and SD (n = 8/group) is presented. Statistical significance was tested with one-way ANOVA test using Tukey’s multiple comparisons test compared to buffer group or as indicated (* p≤0.05; ** p≤0.01; *** p≤0.0001).
Fig 2 Induction of rabies virus specific T cells upon immunization of female BALB/c mice with RABV-G mRNA. Mice were vaccinated twice (days 0 and 21) with 80 μg RABV-G mRNA, 0.1 human dose Rabipur (LIC) or buffer. Activated, antigen specific (A) CD8+ T cells and (B) CD4+ T cells were analyzed by intracellular staining of IFN-γ alone (left panel), TNFα alone (middle panel) or IFN-γ and TNFα (right panel) followed by flow cytometry analysis. Isolation of splenocytes was done 6 days after the second immunization. (C+D) Analysis of long-lasting T cell immunoreactivity. Mice were treated with 80 μg RABV-G mRNA, 0.1 human dose Rabipur (LIC) or injection buffer alone at days 0 and 21. Ten weeks after boost, animals were sacrificed and IFN-γ and TNFα double positive antigen-specific (C) CD8+ and (D) CD4+ T cells were analysed by flow cytometry (n = 8/group). Mean and SD (n = 8/group) is presented. Statistical significance was tested with one-way ANOVA test using Tukey’s multiple comparisons test compared to buffer group or as indicated (* p≤0.05; ** p≤0.01; *** p≤0.0001).CC BY · PubMed Central
Fig 3 Protective capacity of mRNA vaccine against lethal intracerebal (i.c.) rabies challenge infection. Female BALB/c mice were vaccinated twice (days 0 and 21) with 80 μg RABV-G mRNA, 0.1 human dose HDC or injection buffer alone as negative control. Six weeks after the second immunization, mice were infected i.c. with rabies virus. (A) Survival of challenged mice is illustrated by a Kaplan-Meyer-analysis. (B) Body weight of challenged mice was monitored daily. As soon as animals lost 25% of initial body weight (dotted line), animals were sacrificed for reasons of humane endpoint criteria (n = 5 /group). Mean and SD is presented.
Fig 3 Protective capacity of mRNA vaccine against lethal intracerebal (i.c.) rabies challenge infection. Female BALB/c mice were vaccinated twice (days 0 and 21) with 80 μg RABV-G mRNA, 0.1 human dose HDC or injection buffer alone as negative control. Six weeks after the second immunization, mice were infected i.c. with rabies virus. (A) Survival of challenged mice is illustrated by a Kaplan-Meyer-analysis. (B) Body weight of challenged mice was monitored daily. As soon as animals lost 25% of initial body weight (dotted line), animals were sacrificed for reasons of humane endpoint criteria (n = 5 /group). Mean and SD is presented.CC BY · PubMed Central
Fig 4 qRT-PCR analysis of viral N-protein encoding RNA and cellular TNFα mRNA transcript levels in brains 3 and 6 days after i.c. rabies challenge infection. Female BALB/c mice were injected with buffer alone (white bar), 80 μg RABV-G mRNA (black bar) or 0.1 human dose Rabipur (grey bar), on study days 0 and 21. 5 weeks after second immunization, mice were i.c. infected (into the telencephalon) with rabies virus. 3 and 6 days thereafter, mice were sacrificed. Perfused brains were divided into telencephalon (left panel) and cerebellum (right panel) and tested by qRT-PCR. (A) Detection of viral N-protein RNA. Ct-values are illustrated with a N-protein RNA detection limit of 33 cycles (grey line). Ct-values below the detection limit are positive for virus RNA as indicated in the figure. Bars represent the mean and SD (n = 4/group). Significance between the buffer control group (white bar) and immunized groups was calculated using the one-way ANOVA Tukey’s multiple comparison test (* p<0.05). (B) TNFα mRNA levels in the telencephalon (left panel) and cerebellum (right panel). RNA of brains from uninfected animals served as control. mRNA values of controls were defined as “1” (dotted line). Fold changes were calculated and bars represent the mean and SD (n = 4/group). Statistical significance to uninfected controls was tested with one-way ANOVA Tukey’s multiple comparison test with a significance level of 5% (*).
Fig 4 qRT-PCR analysis of viral N-protein encoding RNA and cellular TNFα mRNA transcript levels in brains 3 and 6 days after i.c. rabies challenge infection. Female BALB/c mice were injected with buffer alone (white bar), 80 μg RABV-G mRNA (black bar) or 0.1 human dose Rabipur (grey bar), on study days 0 and 21. 5 weeks after second immunization, mice were i.c. infected (into the telencephalon) with rabies virus. 3 and 6 days thereafter, mice were sacrificed. Perfused brains were divided into telencephalon (left panel) and cerebellum (right panel) and tested by qRT-PCR. (A) Detection of viral N-protein RNA. Ct-values are illustrated with a N-protein RNA detection limit of 33 cycles (grey line). Ct-values below the detection limit are positive for virus RNA as indicated in the figure. Bars represent the mean and SD (n = 4/group). Significance between the buffer control group (white bar) and immunized groups was calculated using the one-way ANOVA Tukey’s multiple comparison test (* p<0.05). (B) TNFα mRNA levels in the telencephalon (left panel) and cerebellum (right panel). RNA of brains from uninfected animals served as control. mRNA values of controls were defined as “1” (dotted line). Fold changes were calculated and bars represent the mean and SD (n = 4/group). Statistical significance to uninfected controls was tested with one-way ANOVA Tukey’s multiple comparison test with a significance level of 5% (*).CC BY · PubMed Central
Fig 5 CD4+ T cell depletion during immunization phase followed by challenge infection. Female BALB/c mice were vaccinated with RABV-G mRNA, Rabipur (LIC) or injection buffer alone on days 0 and 21. The CD4+ T cell population was specifically depleted in one mRNA-receiving group by injection of anti-CD4 antibody on days -1, 1, 20 and 22. (A) Evaluation of rabies virus neutralizing antibodies in sera of control, vaccinated or vaccinated and CD4-depleted mice 4 weeks after the second immunization using the FAVN test (n = 8/group). Mean and SD is presented. Significance between the buffer control group and immunized groups was calculated using the one-way ANOVA Tukey’s multiple comparison test (* p<0.05). (B, C) Mice were challenged with a lethal dose of rabies virus and (B) body weight was monitored daily. A loss of 25% of initial body weight was defined as humane endpoint. Mean and SD is presented. (C) Survival of challenged mice. # note: the sacrificed mouse in the RABV-G mRNA (black diamond) group was excluded from the body weight analysis to demonstrate the healthy state of the remaining animals. This mouse was also negative for rabies specific antibodies (see Fig 5A).
Fig 5 CD4+ T cell depletion during immunization phase followed by challenge infection. Female BALB/c mice were vaccinated with RABV-G mRNA, Rabipur (LIC) or injection buffer alone on days 0 and 21. The CD4+ T cell population was specifically depleted in one mRNA-receiving group by injection of anti-CD4 antibody on days -1, 1, 20 and 22. (A) Evaluation of rabies virus neutralizing antibodies in sera of control, vaccinated or vaccinated and CD4-depleted mice 4 weeks after the second immunization using the FAVN test (n = 8/group). Mean and SD is presented. Significance between the buffer control group and immunized groups was calculated using the one-way ANOVA Tukey’s multiple comparison test (* p<0.05). (B, C) Mice were challenged with a lethal dose of rabies virus and (B) body weight was monitored daily. A loss of 25% of initial body weight was defined as humane endpoint. Mean and SD is presented. (C) Survival of challenged mice. # note: the sacrificed mouse in the RABV-G mRNA (black diamond) group was excluded from the body weight analysis to demonstrate the healthy state of the remaining animals. This mouse was also negative for rabies specific antibodies (see Fig 5A).CC BY · PubMed Central
Fig 6 Seroconversion profile after RABV-G mRNA and Rabipur (LIC) vaccination in domestic pigs. Immunization points are indicated by arrows. (A) Adult pigs received intradermal immunizations on days 0, 14, 49 with either 80 μg RABV-G mRNA or injection buffer alone. At different time points after immunization, sera were tested for rabies-specific neutralizing antibodies using FAVN testing (n = 6 pigs/group). (B) Newborn piglets were immunized in their first week of life and 3 weeks later with 80 μg or 240 μg RABV-G mRNA (i.d.) or a full human dose of Rabipur (LIC; i.m.). As a negative control, animals were immunized with 240 μg of an irrelevant mRNA. At different time points blood samples were taken and sera were tested for virus-neutralizing antibodies using the FAVN test (n = 5 or n = 6 (240 μg) piglets/group). In both graphs mean and SD is illustrated.
Fig 6 Seroconversion profile after RABV-G mRNA and Rabipur (LIC) vaccination in domestic pigs. Immunization points are indicated by arrows. (A) Adult pigs received intradermal immunizations on days 0, 14, 49 with either 80 μg RABV-G mRNA or injection buffer alone. At different time points after immunization, sera were tested for rabies-specific neutralizing antibodies using FAVN testing (n = 6 pigs/group). (B) Newborn piglets were immunized in their first week of life and 3 weeks later with 80 μg or 240 μg RABV-G mRNA (i.d.) or a full human dose of Rabipur (LIC; i.m.). As a negative control, animals were immunized with 240 μg of an irrelevant mRNA. At different time points blood samples were taken and sera were tested for virus-neutralizing antibodies using the FAVN test (n = 5 or n = 6 (240 μg) piglets/group). In both graphs mean and SD is illustrated.CC BY · PubMed Central

Verification

Claims the paper makes

53 Own result · 20 Own interpretation · 9 No full text of the sources · 4 Own method · 2 Supported so far · 2 Partly supported · 2 Sources not found · 2 No basis given · 1 Supported · 1 Not checked yet · accuracy not yet measured

Verify all 1 references — free account

Show all 50 claims

  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 36
  • The quote only partly states this claim. 1
46 of 46
  • The paper relies on this without support.

    Rabies virus infection in unvaccinated or untreated subjects is invariably fatal.

    “In unvaccinated or untreated subjects, rabies virus infection causes severe neurological symptoms and is invariably fatal.”
  • The paper relies on this without support.

    Nucleic acid based vaccines are a proven technology for fast development of vaccines against newly emerging pathogens, diseases where no vaccine exists, or for replacing existing vaccines.

    “Nucleic acid based vaccines have proven convincingly as a new technology for the fast development of vaccines against newly emerging pathogens, diseases where no vaccine exists or for replacing already existing vaccines.”
  • The paper relies on this without support.

    Virus neutralizing antibody titers above 0.5 IU/ml correlate with protection against rabies in adult and newborn pigs.

    “In domestic pigs we were able to induce VN titers that correlate with protection in adult and newborn pigs.”
  • The paper relies on this without support.

    Intracerebral infection is accepted by the scientific community as a stringent experimental test for rabies vaccines.

    “Intracerebral infection poses an extremely harsh challenge that is artificial, but accepted by the scientific community as a stringent experimental test.”
  • The paper relies on this without support.

    Pre-existing immunity was not expected to affect experimental outcomes, especially in pigs.

    “Unlike in the case of influenza, pre-existing immunity was not expected to affect experimental outcomes especially in pigs.”
  • The authors state this as an assumption.

    The new mRNA vaccination strategy may be extended to the prophylaxis and treatment of infectious diseases in general.

    “further substantiate the assumption that this new vaccination strategy may be extended to the prophylaxis and treatment of infectious diseases in general.”
6 of 6

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. LJMH Reed, 1938, A simple method of estimation of fifty percent end points, Am J Hyg, 27, 493

Cited by

Sorted by citations

See all 212

Metadata

Authors
Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L.
Affiliations
  • CureVac (Germany) (DE)
  • Friedrich-Loeffler-Institut (DE)
Corresponding author
  • Petsch, Benjamin
  • Stitz, Lothar
Venue
PLOS Neglected Tropical Diseases
Published
2016-06-23
Volume
10
Issue
6
Pages
e0004746
ISSN
  • 1935-2727 (ISSN-L)
  • 1935-2735
OpenAlex
W2465126304
Cited by
212
References
60
Citations by year
2026: 8 · 2025: 19 · 2024: 28 · 2023: 35 · 2022: 31 · 2021: 38 · 2020: 22 · 2019: 7 · 2018: 10 · 2017: 9 · 2016: 4
FWCI
6.32
Type
journal article
Language
en
Open access
Locations
  • PLoS neglected tropical diseases (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • OpenAgrar (submittedVersion)
Funders
KMU-innovativ (031A061C, 031A061A, 0315802)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › Rabies epidemiology and control
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
rabies virus, rabies virus glycoprotein, mRNA vaccines, nucleic acid vaccines, neutralizing antibodies, CD4+ T cells, CD8+ T cells, vaccine protection, newborn pigs, intracerebral challenge, antibody persistence
MeSH terms
Animals, Animals, Newborn, Base Sequence, Dose-Response Relationship, Immunologic, Female, Glycoproteins, HeLa Cells, Humans, Mice, Inbred BALB C, Mice, Inbred C57BL, Peptide Fragments, Pregnancy, Rabies, Rabies Vaccines, RNA, Messenger, Swine, Swine Diseases, T-Lymphocytes, Vaccines, Synthetic, Viral Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review